Adam Crystal

4.7k total citations · 1 hit paper
28 papers, 1.6k citations indexed

About

Adam Crystal is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Adam Crystal has authored 28 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Adam Crystal's work include Alzheimer's disease research and treatments (9 papers), Advanced Breast Cancer Therapies (8 papers) and HER2/EGFR in Cancer Research (4 papers). Adam Crystal is often cited by papers focused on Alzheimer's disease research and treatments (9 papers), Advanced Breast Cancer Therapies (8 papers) and HER2/EGFR in Cancer Research (4 papers). Adam Crystal collaborates with scholars based in United States, Italy and Singapore. Adam Crystal's co-authors include Viviana Cremasco, Sonia Quaratino, Britta Mueller, Philip J. Gotwals, Jeffrey A. Engelman, Becker Hewes, Catherine Sabatos-Peyton, Daniela Cipolletta, Scott B. Cameron and Glenn Dranoff and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Adam Crystal

27 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospects for combining targeted and conventional cancer therapy with immunotherapy

2017 766 citations Philip J. Gotwals, Scott B. Cameron et al. Nature reviews. Cancer profile →

Peers

Adam Crystal

ONCOL

PHYSI

PRM

IMMUN

Christine Tan United States

Houjie Liang China

Yu-Chen Lee United States

Marie O. Péquignot France

Timothy G. Pestell United States

Ines Lohse United States

Giuseppina Comito Italy

Ganfeng Xie China

Aijun Zhang United States

Izabela Piotrowska United Kingdom

Christine Tan United States

Adam Crystal

487 ×0.8

ONCOL

1.2k ×2.0

150 ×0.4

PHYSI

143 ×0.4

PRM

318 ×1.0

IMMUN

Citations per year, relative to Adam Crystal Adam Crystal (= 1×) peers Christine Tan

Countries citing papers authored by Adam Crystal

Since Specialization

Citations

This map shows the geographic impact of Adam Crystal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Crystal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Crystal more than expected).

Fields of papers citing papers by Adam Crystal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Crystal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Crystal. The network helps show where Adam Crystal may publish in the future.

Co-authorship network of co-authors of Adam Crystal

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Crystal. A scholar is included among the top collaborators of Adam Crystal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Crystal. Adam Crystal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Minjie, Alice Tsai, Kevin M. Cottrell, et al.. (2025). Abstract 2996: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models. Cancer Research. 85(8_Supplement_1). 2996–2996. 1 indexed citations

Simoneau, Antoine, Hsin‐Jung Wu, Charlotte Pratt, et al.. (2024). Abstract 4527: TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress. Cancer Research. 84(6_Supplement). 4527–4527. 1 indexed citations

Mignault, André A., Douglas A. Whittington, Satoshi Yoda, et al.. (2024). Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors. Cancer Research. 84(6_Supplement). 4631–4631.

Ahronian, Leanne G., Minjie Zhang, Alborz Bejnood, et al.. (2023). 870 CoREST inhibition by TNG260 increases expression of immunomodulatory genes in STK11-mutant cancer and sensitizes to immune checkpoint blockade. SHILAP Revista de lepidopterología. A969–A969. 1 indexed citations

Isasa, Marta, Roman V. Agafonov, Prasoon Chaturvedi, et al.. (2021). CFT7455: A NOVEL, IKZF1/3 DEGRADER THAT DEMONSTRATES POTENT TUMOR REGRESSION IN A SPECTRUM OF NHL XENOGRAFT MODELS. Hematological Oncology. 39(S2). 3 indexed citations

Berdeja, Jesús G., Sikander Ailawadhi, Steven M. Horwitz, et al.. (2021). A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 1675–1675. 18 indexed citations

Jhaveri, Komal, Dejan Juric, Sara Cresta, et al.. (2020). LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET). Annals of Oncology. 31. S62–S62. 7 indexed citations

Gotwals, Philip J., Scott B. Cameron, Daniela Cipolletta, et al.. (2017). Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature reviews. Cancer. 17(5). 286–301. 766 indexed citations breakdown →

Infante, Jeffrey R., Philippe A. Cassier, John F. Gerecitano, et al.. (2016). A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 22(23). 5696–5705. 237 indexed citations

10.

Crystal, Adam & Alice T. Shaw. (2012). Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?. Clinical Cancer Research. 18(17). 4479–4481. 11 indexed citations

11.

Crystal, Adam & Alice T. Shaw. (2011). New targets in advanced NSCLC: EML4-ALK.. PubMed. 9(3). 207–14. 27 indexed citations

12.

Morais, Vanessa A., Catarina Brito, Donald S. Pijak, et al.. (2006). N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1762(9). 802–810. 16 indexed citations

13.

Fortna, Ryan R., Adam Crystal, Vanessa A. Morais, et al.. (2004). Membrane Topology and Nicastrin-enhanced Endoproteolysis of APH-1, a Component of the γ-Secretase Complex. Journal of Biological Chemistry. 279(5). 3685–3693. 58 indexed citations

14.

Crystal, Adam, Vanessa A. Morais, Theodore C. Pierson, et al.. (2003). Membrane Topology of γ-Secretase Component PEN-2. Journal of Biological Chemistry. 278(22). 20117–20123. 71 indexed citations

15.

Morais, Vanessa A., Adam Crystal, Donald S. Pijak, et al.. (2003). The Transmembrane Domain Region of Nicastrin Mediates Direct Interactions with APH-1 and the γ-Secretase Complex. Journal of Biological Chemistry. 278(44). 43284–43291. 61 indexed citations

16.

Crystal, Adam, Benoit I. Giasson, Mei‐Ping Kung, et al.. (2003). A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. Journal of Neurochemistry. 86(6). 1359–1368. 122 indexed citations

17.

Price, R. Arlen, et al.. (2001). A locus affecting obesity in human chromosome region 10p12. Diabetologia. 44(3). 363–366. 52 indexed citations

18.

Bertram, Lars, Jennifer Jones, Devon B. Keeney, et al.. (2001). No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Annals of Neurology. 49(1). 114–116. 24 indexed citations

19.

Bertram, Lars, Deborah Blacker, Adam Crystal, et al.. (2000). Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies. Experimental Gerontology. 35(9-10). 1353–1361. 47 indexed citations

20.

Guénette, Suzanne Y., Adam Crystal, Benjamin Bakondi, et al.. (2000). Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients. Neuroscience Letters. 296(1). 17–20. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact